Thu, Mar. 19, 1:29 PM
- Investors show some love for CAR-T-related stocks today. Drugs based on Chimeric Antigen Receptor technology are the "next big things" in cancer treatment. Early data show impressive results in certain blood cancers.
- Newcomer Cellectis (Pending:CLLS) should debut shortly.
- Related tickers: (JUNO +14.8%)(KITE +14.9%)(BLUE +5.2%)(BLCM +7.7%)(ZIOP +4.6%)(CNDO +40.1%)
Tue, Feb. 10, 9:16 AM
Tue, Feb. 10, 9:06 AM
- Intrexon (NYSE:XON) and Ziopharm (NASDAQ:ZIOP) are up 11% and 5%, respectively, premarket on higher-than-normal volume. Shares appear poised to resume their up moves after the pops in mid-January in response to their joint license deal with MD Anderson Cancer Center for the development of CAR-T cancer therapies. Under the collaboration, up to five CARs are expected to enter the clinic this year with off-the-shelf programs expected to start in 2016.
- Previously: Ziopharm up big on CAR-T license deal (Jan. 14)
Tue, Feb. 3, 9:05 AM
Tue, Jan. 27, 12:40 PM
Wed, Jan. 14, 12:43 PM
Wed, Jan. 14, 9:17 AM
Wed, Jan. 14, 8:25 AM
- Ziopharm (NASDAQ:ZIOP) jumps 50% premarket on robust volume in response to its announcement of an exclusive license deal with partner Intrexon (NYSE:XON) (+12%) with The University of Texas MD Anderson Cancer Center covering technology and intellectual property related to non-viral adoptive cellular cancer immunotherapies. The technologies originate from two researchers who have pioneered the design and clinical investigation of chimeric antigen receptor (CAR) T cell therapies for the potential treatment of cancer using non-viral gene integration platforms.
- The two researchers are Laurence Cooper, M.D., Ph.D, professor of pediatrics at MD Anderson who has expertise in immunotherapies and Perry Hackett, Ph.D., professor within the College of Biological Sciences at Minnesota, who discovered and developed a system called Sleeping Beauty, a non-viral DNA plasmid-based gene transfer system.
- The deal brings the CAR-T technology together Intrexon's technology suite and Ziopharm's clinically tested RheoSwitch Therapeutic System interleukin-12 modules. Up to five CARs are expected to enter the clinic this year and off-the-shelf programming initiating in 2016.
- Under the terms of the agreement, MD Anderson will receive $100M from the companies in the form of $50M of common stock from each firm. In addition, the companies have committed $15M - 20M over each of the next three years for researching and developing the technologies.
- CAR-T therapies are the "next big thing" in cancer treatment.
- Related tickers: (NASDAQ:KITE) (NASDAQ:JUNO) (NASDAQ:AMGN) (NYSE:NVS) (NYSE:JNJ)
Mon, Jan. 12, 9:14 AM
Nov. 14, 2014, 12:46 PM
May. 23, 2014, 9:10 AM
May. 22, 2014, 4:56 PM
- Ziopharm Oncology (ZIOP) +7.3% AH after announcing results for its Ad-RTS-IL-12 DNA-based therapeutic candidate for the controlled expression of IL-12 correlate with reduced cancer stem cells in the brain.
- ZIOP says the results demonstrate potent anti-tumor and anti-cancer stem cell effects in a brain cancer model, and in other preclinical and clinical settings.
Mar. 20, 2014, 1:09 PM
Mar. 20, 2014, 9:12 AM
Mar. 4, 2014, 10:54 AM
- Shares of ZIOPHARM Oncology (ZIOP +10.7%) get a post-report tailwind.
- Investors like its collaboration with Intrexon (XON) for its RheoSwitch Therapeutic System, a method for modulating protein production in gene-based therapies.
- The company's lead product, Ad-RTS-IL-12, a novel gene expression platform for interleukin-12, is currently in P2 trials for the treatment of melanoma and breast cancer.
- Quick assets totaled $68.2M at years end and will be sufficient to fund operations into 2015's second quarter.
- Earnings release
Dec. 16, 2013, 9:11 AM
ZIOP vs. ETF Alternatives
ZIOPHARM Oncology Inc is a biopharmaceutical company. The Company is engaged in the acquiring, developing and commercializing portfolio of cancer therapies that can address unmet medical needs through synthetic biology.
Other News & PR